Quantitative prediction of glucuronidation in humans using the in vitro-in vivo extrapolation approach

Current Topics in Medicinal Chemistry

Volumn 13, Issue 11, 2013, Pages 1343-1352

  Wu, Baojian ^a   Dong, Dong ^b   Hu, Ming ^b   Zhang, Shuxing ^c  

^a JINAN UNIVERSITY   (China)

^b UNIVERSITY OF HOUSTON   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Drug metabolism; Glucuronidation; In vitro in vitro correlation; In vitro in vitro extrapolation; Quantitative prediction; UGTs

Indexed keywords

BUPRENORPHINE; CODEINE; DICLOFENAC; FLUCONAZOLE; GEMFIBROZIL; GLUCURONOSYLTRANSFERASE 1A7; GLUCURONOSYLTRANSFERASE 1A8; GLUCURONOSYLTRANSFERASE 1A9; KETAMINE; KETOPROFEN; LAMOTRIGINE; METHADONE; MIDAZOLAM; MORPHINE; MYCOPHENOLIC ACID; NALOXONE; PROPOFOL; QUERCETIN; RALOXIFENE; SALBUTAMOL; TELMISARTAN; TROGLITAZONE; VALPROIC ACID; ZIDOVUDINE;

AREA UNDER THE CURVE; ARTICLE; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG GLUCURONIDATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INTESTINE; KIDNEY METABOLISM; LIVER CELL; LIVER CLEARANCE; LIVER MICROSOME; PREDICTION; PROTEIN BINDING;

BIOLOGICAL ASSAY; BIOTRANSFORMATION; DRUG EVALUATION, PRECLINICAL; DRUG INTERACTIONS; GLUCURONIDES; HEPATOCYTES; HUMANS; INTESTINES; KINETICS; METABOLIC CLEARANCE RATE; MICROSOMES, LIVER; MODELS, STATISTICAL; PREDICTIVE VALUE OF TESTS; PRESCRIPTION DRUGS; SERUM ALBUMIN, BOVINE;

EID: 84881324657     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/15680266113139990038     Document Type: Article

References (60)

1. Mackenzie, P.I.; Bock, K.W.; Burchell, B.; Guillemette, C.; Ikushiro, S.; Iyanagi, T.; Miners, J.O.; Owens, I.S.; Nebert, D.W. Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily. Pharmacogenet. Genomics. 2005, 15(10), 677-85.
2. Ohno, S.; Nakajin, S. Determination of mRNA expression of human UDP-glucuronosyltransferases and application for localization in various human tissues by real-time reverse transcriptasepolymerase chain reaction. Drug. Metab. Dispos. 2009, 37(1), 32-40.
3. Izukawa, T.; Nakajima, M.; Fujiwara, R.; Yamanaka, H.; Fukami, T.; Takamiya, M.; Aoki, Y.; Ikushiro, S.; Sakaki, T.; Yokoi, T. Quantitative analysis of UDP-glucuronosyltransferase (UGT) 1A and UGT2B expression levels in human livers. Drug. Metab. Dispos. 2009, 37(8), 1759-68.
4. Evans, W.E.; Relling, M.V. Pharmacogenomics: translating functional genomics into rational therapeutics. Science. 1999, 286 (5439), 487-91.
5. Williams, J.A.; Hyland, R.; Jones, B.C.; Smith, D.A.; Hurst, S.; Goosen, T.C.; Peterkin, V.; Koup, J.R.; Ball, S.E. Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/ AUC) ratios. Drug. Metab. Dispos. 2004, 32(11), 1201-8.
6. Houston, J.B. Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem. Pharmacol. 1994, 47(9), 1469-79.
7. Ito, K.; Houston, J.B. Prediction of human drug clearance from in vitro and preclinical data using physiologically based and empirical approaches. Pharm. Res. 2005, 22(1), 103-12.
8. Houston, J.B.; Galetin, A. Methods for predicting in vivo pharmacokinetics using data from in vitro assays. Curr. Drug. Metab. 2008, 9(9), 940-51.
9. Houston, J.B.; Kenworthy, K.E. In vitro-in vivo scaling of CYP kinetic data not consistent with the classical Michaelis-Menten model. Drug. Metab. Dispos. 2000, 28, 246-54.
10. Uchaipichat, V.; Mackenzie, P.I.; Guo, X.H.; Gardner-Stephen, D.; Galetin, A.; Houston, J.B.; Miners, J.O. Human udp-glucuronosyl transferases: isoform selectivity and kinetics of 4-methylumbelli ferone and 1-naphthol glucuronidation, effects of organic solvents, and inhibition by diclofenac and probenecid. Drug. Metab. Dispos. 2004, 32(4), 413-23.
11. Obach, R.S. Nonspecific binding to microsomes: impact on scaleup of in vitro intrinsic clearance to hepatic clearance as assessed through examination of warfarin, imipramine, and propranolol. Drug. Metab. Dispos. 1997, 25(12), 1359-69.
12. Oravcová, J.; Böhs, B.; Lindner, W. Drug-protein binding sites. New trends in analytical and experimental methodology. J. Chromatogr. B. Biomed. Appl. 1996, 677(1), 1-28.
13. Austin, R.P.; Barton, P.; Cockroft, S.L.; Wenlock, M.C.; Riley, R.J. The influence of nonspecific microsomal binding on apparent intrinsic clearance, and its prediction from physicochemical properties. Drug. Metab. Dispos. 2002, 30(12), 1497-503.
14. Hallifax, D.; Houston, J.B. Binding of drugs to hepatic microsomes: comment and assessment of current prediction methodology with recommendation for improvement. Drug. Metab. Dispos. 2006, 34(4), 724-6;
15. Turner, D.B.; Rostami-Hodjegan, A.; Tucker, G.T.; Yeo, K.R. Prediction of nonspecific hepatic microsomal binding from readily available physicochemical properties. Drug. Metab. Rev. 2007, 38(S1), 162.
16. Gertz, M.; Kilford, P.J.; Houston, J.B.; Galetin, A. Drug lipophilicity and microsomal protein concentration as determinants in the prediction of the fraction unbound in microsomal incubations. Drug Metab Dispos. 2008, 36(3), 535-42.
17. Poulin, P.; Haddad, S. Microsome composition-based model as a mechanistic tool to predict nonspecific binding of drugs in liver microsomes. J. Pharm. Sci. 2011, doi: 10.1002/jps.22619.
18. Gao, H.; Steyn, S.J.; Chang, G.; Lin, J. Assessment of in silico models for fraction of unbound drug in human liver microsomes. Expert. Opin. Drug. Metab. Toxicol. 2010, 6(5), 533-42.
19. Ridgway, D.; Tuszynski, J.A.; Tam, Y.K. Reassessing models of hepatic extraction. J. Biol. Phys. 2003, 29(1), 1-21.
20. Pang, K.S.; Rowland, M. Hepatic clearance of drugs. I. Theoretical considerations of a "well-stirred" model and a "parallel tube" model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance. J. Pharmacokinet. Biopharm. 1977, 5(6), 625-53.
21. Roberts, M.S.; Rowland, M. A dispersion model of hepatic elimination: 3. Application to metabolite formation and elimination kinetics. J. Pharmacokinet. Biopharm. 1986, 14(3), 289-308.
22. Liu, L.; Pang, K.S. An integrated approach to model hepatic drug clearance. Eur. J. Pharm. Sci. 2006, 29(3-4), 215-30.
23. Boase, S.; Miners, J.O. In vitro-in vivo correlations for drugs eliminated by glucuronidation: investigations with the model substrate zidovudine. Br. J. Clin. Pharmacol. 2002, 54(5), 493-503.
24. Soars, M.G.; Burchell, B.; Riley, R.J. In vitro analysis of human drug glucuronidation and prediction of in vivo metabolic clearance. J. Pharmacol. Exp. Ther. 2002, 301(1), 382-90.
25. Cubitt, H.E.; Houston, J.B.; Galetin, A. Relative importance of intestinal and hepatic glucuronidation-impact on the prediction of drug clearance. Pharm. Res. 2009, 26(5), 1073-83.
26. Mistry, M.; Houston, J.B. Glucuronidation in vitro and in vivo. Comparison of intestinal and hepatic conjugation of morphine, naloxone, and buprenorphine. Drug. Metab. Dispos. 1987, 15(5), 710-7.
27. Miners, J.O.; Knights, K.M.; Houston, J.B.; Mackenzie, P.I. In vitro-in vivo correlation for drugs and other compounds eliminated by glucuronidation in humans: pitfalls and promises. Biochem. Pharmacol. 2006, 71(11), 1531-9.
28. Miners, J.O.; Mackenzie, P. I; Knights, K.M. The prediction of drug-glucuronidation parameters in humans: UDP-glucuronosyl transferase enzyme-selective substrate and inhibitor probes for reaction phenotyping and in vitro-in vivo extrapolation of drug clearance and drug-drug interaction potential. Drug. Metab. Rev. 2010, 42(1), 196-208.
29. Rowland, A.; Gaganis, P.; Elliot, D.J.; Mackenzie, P.I.; Knights, K.M.; Miners, J.O. Binding of inhibitory fatty acids is responsible for the enhancement of UDP-glucuronosyltransferase 2B7 activity by albumin: implications for in vitro-in vivo extrapolation. J. Pharmacol. Exp. Ther. 2007, 321(1), 137-47
30. Rowland, A.; Knights, K.M.; Mackenzie, P.I.; Miners, J.O. The "albumin effect" and drug glucuronidation: bovine serum albumin and fatty acid-free human serum albumin enhance the glucuronidation of UDP-glucuronosyltransferase (UGT) 1A9 substrates but not UGT1A1 and UGT1A6 activities. Drug. Metab. Dispos. 2008, 36(6), 1056-62.
31. Rowland, A.; Knights, K.M.; Mackenzie, P.I.; Miners, J.O. Characterization of the binding of drugs to human intestinal fatty acid binding protein (IFABP): potential role of IFABP as an alternative to albumin for in vitro-in vivo extrapolation of drug kinetic parameters. Drug. Metab. Dispos. 2009, 37(7), 1395-403.
32. Manevski, N.; Moreolo, P.S.; Yli-Kauhaluoma, J.; Finel, M. Bovine serum albumin decreases Km values of human UDPglucuronosyltransferases 1A9 and 2B7 and increases Vmax values of UGT1A9. Drug. Metab. Dispos. 2011, 39(11), 2117-29.
33. Kilford, P.J.; Stringer, R.; Sohal, B.; Houston, J.B.; Galetin, A. Prediction of drug clearance by glucuronidation from in vitro data: use of combined cytochrome P450 and UDPglucuronosyltransferase cofactors in alamethicin-activated human liver microsomes. Drug. Metab. Dispos. 2009, 37(1), 82-9.
34. Gill, K.L.; Houston, J.B.; Galetin, A. Characterization of in vitro glucuronidation clearance of a range of drugs in human kidney microsomes: comparison with liver and intestinal glucuronidation and impact of albumin. Drug. Metab. Dispos. 2012, 40(4), 825-35.
35. Cubitt, H.E.; Houston, J.B.; Galetin, A. Prediction of human drug clearance by multiple metabolic pathways: integration of hepatic and intestinal microsomal and cytosolic data. Drug. Metab. Dispos. 2011, 39(5), 864-73
36. Engtrakul, J.J.; Foti, R.S.; Strelevitz, T.J.; Fisher, M.B. Altered AZT (3'-azido-3'-deoxythymidine) glucuronidation kinetics in liver microsomes as an explanation for underprediction of in vivo clearance: comparison to hepatocytes and effect of incubation environment. Drug. Metab. Dispos. 2005, 33(11), 1621-7.
37. Foster, J.A.; Hallifax, D.; Houston, J.B. How robust is the prediction of in vivo metabolic clearance from established in vitro systems? Drug. Metab. Rev. 2009, 41(Suppl 1), 26.
38. Yang, J.; Jamei, M.; Yeo, K.R.; Tucker, G.T.; Rostami-Hodjegan, A. Prediction of intestinal first-pass drug metabolism. Curr. Drug. Metab. 2007, 8(7), 676-84.
39. Gertz, M.; Harrison, A.; Houston, J.B.; Galetin, A. Prediction of human intestinal first-pass metabolism of 25 CYP3A substrates from in vitro clearance and permeability data. Drug. Metab. Dispos. 2010, 38(7), 1147-58.
40. Nishimuta, H.; Sato, K.; Mizuki, Y.; Yabuki, M.; Komuro, S. Prediction of the intestinal first-pass metabolism of CYP3A substrates in humans using cynomolgus monkeys. Drug. Metab. Dispos. 2010, 38(11), 1967-75.
41. Nishimuta, H.; Sato, K.; Yabuki, M.; Komuro, S. Prediction of the intestinal first-pass metabolism of CYP3A and UGT substrates in humans from in vitro data. Drug. Metab Pharmacokinet. 2011;26(6):592-601.
42. Furukawa, T.; Yamano, K.; Naritomi, Y.; Tanaka, K.; Terashita, S.; Teramura, T. Method for predicting human intestinal first-pass metabolism of UGT substrate compounds. Xenobiotica. 2012, 42(10), 980-8.
43. Rowland, A.; Elliot, D.J.; Williams, J.A.; Mackenzie, P.I.; Dickinson, R.G.; Miners, J.O. In vitro characterization of lamotrigine N2-glucuronidation and the lamotrigine-valproic acid interaction. Drug. Metab. Dispos. 2006, 34(6), 1055-62.
44. Ito, K,; Brown, H.S.; Houston, J.B. Database analyses for the prediction of in vivo drug-drug interactions from in vitro data. Br. J. Clin. Pharmacol. 2004, 57(4), 473-86.
45. Uchaipichat, V.; Winner, L.K.; Mackenzie, P.I.; Elliot, D.J.; Williams, J.A.; Miners, J.O. Quantitative prediction of in vivo inhibitory interactions involving glucuronidated drugs from in vitro data: the effect of fluconazole on zidovudine glucuronidation. Br. J. Clin. Pharmacol. 2006, 61(4), 427-39.
46. Gertz, M.; Houston, J.B.; Galetin, A. Physiologically based pharmacokinetic modeling of intestinal first-pass metabolism of CYP3A substrates with high intestinal extraction. Drug. Metab. Dispos. 2011, 39(9), 1633-42.
47. Gerber, S.A.; Rush, J.; Stemman, O.; Kirschner, M.W.; Gygi, S.P. Absolute quantification of proteins and phosphoproteins from cell lysates by tandem MS. Proc. Natl. Acad. Sci. USA. 2003, 100(12), 6940-5.
48. Hallifax, D.; Houston, J.B. Saturable uptake of lipophilic amine drugs into isolated hepatocytes: mechanisms and consequences for quantitative clearance prediction. Drug. Metab. Dispos. 2007, 35(8), 1325-32.
49. Hallifax, D.; Houston, J.B. Uptake and intracellular binding of lipophilic amine drugs by isolated rat hepatocytes and implications for prediction of in vivo metabolic clearance. Drug. Metab. Dispos. 2006, 34(11), 1829-36.
50. Parker, A.J.; Houston, J.B. Rate-limiting steps in hepatic drug clearance: comparison of hepatocellular uptake and metabolism with microsomal metabolism of saquinavir, nelfinavir, and ritonavir. Drug. Metab. Dispos. 2008, 36(7), 1375-84.
51. Wu, B. Pharmacokinetic interplay of phase II metabolism and transport: a theoretical study. J Pharm Sci. 2012, 101(1), 381-93.
52. Hu, M.; Chen, J.; Lin, H. Metabolism of flavonoids via enteric recycling: mechanistic studies of disposition of apigenin in the Caco-2 cell culture model. J. Pharmacol. Exp. Ther. 2003, 307(1), 314-21.
53. Jia, X.; Chen, J.; Lin, H.; Hu, M. Disposition of flavonoids via enteric recycling: enzyme-transporter coupling affects metabolism of biochanin A and formononetin and excretion of their phase II conjugates. J. Pharmacol. Exp. Ther. 2004, 310(3), 1103-13.
54. Raungrut, P.; Uchaipichat, V.; Elliot, D.J.; Janchawee, B.; Somogyi, A.A.; Miners, J.O. In vitro-in vivo extrapolation predicts drugdrug interactions arising from inhibition of codeine glucuronidation by dextropropoxyphene, fluconazole, ketoconazole, and methadone in humans. J. Pharmacol. Exp. Ther, 2010, 334(2), 609-18.
55. Uchaipichat, V.; Raungrut, P.; Chau, N.; Janchawee, B.; Evans, AM.; Miners, J.O. Effects of ketamine on human UDPglucuronosyltransferases in vitro predict potential drug-drug interactions arising from ketamine inhibition of codeine and morphine glucuronidation. Drug. Metab. Dispos, 2011, 39(8):1324-8.
56. Sahai, J.; Gallicano, K.; Pakuts, A.; Cameron, D.W. Effect of fluconazole on zidovudine pharmacokinetics in patients infected with human immunodeficiency virus. J. Infect. Dis. 1994, 169(5), 1103-7.
57. Lertora, J.J.; Rege, A.B.; Greenspan, D.L.; Akula, S.; George, W.J.; Hyslop, N.E. Jr. Agrawal, K.C. Pharmacokinetic interaction between zidovudine and valproic acid in patients infected with human immunodeficiency virus. Clin. Pharmacol. Ther. 1994, 56(3), 272-8.
58. Sato, Y.; Nagata, M.; Kawamura, A.; Miyashita, A.; Usui, T. Protein quantification of UDP-glucuronosyltransferases 1A1 and 2B7 in human liver microsomes by LC-MS/MS and correlation with glucuronidation activities. Xenobiotica. 2012, 42(9), 823-9.
59. Harbourt, D.E.; Fallon, J.K.; Ito, S.; Baba, T.; Ritter, J.K.; Glish, G.L.; Smith, P.C. Quantification of human uridine-diphosphate glucuronosyl transferase 1A isoforms in liver, intestine, and kidney using nanobore liquid chromatography-tandem mass spectrometry. Anal. Chem. 2012, 84(1), 98-105.
60. Ohtsuki, S.; Schaefer, O.; Kawakami, H.; Inoue, T.; Liehner, S.; Saito, A.; Ishiguro, N.; Kishimoto, W.; Ludwig-Schwellinger, E.; Ebner, T.; Terasaki, T. Simultaneous absolute protein quantification of transporters, cytochromes P450, and UDP-glucuronosyl transferases as a novel approach for the characterization of individual human liver: comparison with mRNA levels and activities. Drug. Metab. Dispos. 2012, 40(1), 83-92.